Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï¿¡¼­ ¼ö¼úÈÄ ¹æ»ç¼± Ä¡·á °á°ú Results of Postoperative Radiation Therapy in 77 Patients of Breast Cancer

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 6È£ p.1049 ~ 1060
¼Ò¼Ó »ó¼¼Á¤º¸
±è¿¬½Ç/Yeon Shil Kim ÀåÈ«¼®/À¯¹Ì·É/±è¼ºÈ¯/Á¤»ó¼³/À±¼¼Ã¶/±èÀÎö/½Å°æ¼·/Hong Seok Jang/Mi Ryeong Ryu/Sung Hwan Kim/Sang Sul Chung/Sei Chul Yoon/In Chul Kim/Kyung Sub Shinn

Abstract

¼­·Ð
Àü ¼¼°èÀûÀ¸·Î »õ·Î Áø´ÜµÇ´Â À¯¹æ¾ÏÀÇ 20¡­40%´Â Àü½ÅÀû ÀüÀÌ´Â ¾øÀ¸³ª º´±â T3-4 ÀÌ
°Å³ª ¾×¿Í¸²ÇÁÀý ÀüÀÌ°¡ ÀÖ´Â ±¹¼ÒÁøÇàµÈ ÇüÅÂÀÌ´Ù. ÀÌ·¯ÇÑ °æ¿ì ±ÙÄ¡ÀûÀ¯¹æ ÀýÁ¦¼úÀ» ½ÃÇà
ÇÏ¿©µµ ÀÜÁ¸À¯¹æÁ¶Á÷ ¹× ÁÖº¯ ÇǺÎ, ¿¬ºÎÁ¶Á÷, ¸²ÇÁÁ¶Á÷¿¡ ³²¾ÆÀÖ´Â ÀáÀ纴¼Ò(occult tumor)
´Â ±¹¼ÒÀû Àü½ÅÀûÀç¹ßÀÇ ¿øÀÎÀÌ µÇ¸ç ÀÏ´Ü Àç¹ßÇÑ °æ¿ì ±¸Á¦À²Àº ¸Å¿ì ³·´Ù. ÀÌÁ¦±îÁö ¿©·¯
¿¬±¸º¸°í °á°ú ±¹¼ÒÁøÇàµÈ ÀýÁ¦°¡´ÉÇÑ À¯¹æ¾Ï ȯÀÚ¿¡¼­ ÀûÀýÇÑ ±¹¼ÒÀû Ä¡·á¹æ¹ýÀ¸·Î
(optimal locoregional treatment) ÀüÀ¯¹æÀýÁ¦¼ú°ú ¼ö¼úÈÄ ¹æ»ç¼±Ä¡·áÀÇ º´ÇÕÄ¡·á°¡ ¼ö¼ú´Üµ¶
ȤÀº ¹æ»ç¼±Ä¡·á´Üµ¶ º¸´Ù È¿°úÀûÀÓÀÌ ¹àÇôÁ³´Ù. BedwinekµîÀÌ ¹æ»ç¼± Ä¡·á´Üµ¶°ú ¼ö¼úÈÄ
¹æ»ç¼±Ä¡·áÀÇ º´ÇÕÄ¡·á°á°ú¸¦ ºñ±³ÇÑ °á°ú ±¹¼ÒÁ¦¾î·üÀÌ 35%¿¡¼­ 87%·Î Çâ»óµÇ¾úÀ½À» º¸
°íÇÏ¿´°í, JCRT(Joint Center of Radiotherapy)ÀÇ Uematsuµµ À¯¹æÀýÁ¦ÈÄ ¹æ»ç¼±Ä¡·á¸¦ ½Ã
ÇàÇÑ º´±â ¥²a ȯÀÚÀÇ 10³â ±¹¼ÒÀç¹ß·üÀÌ 14%, º´±â ¥²b ȯÀÚ¿¡¼­´Â 7%ÀÓÀ» º¸°íÇÏ¿´´Ù.
¶ÇÇÑ MDAC-C(M.D. Anderson Cancer Center)ÀÇ Stromµµ À¯¹æÀýÁ¦¼úÈÄ ¹æ»ç¼±Ä¡·á¸¦ ½Ã
ÇàÇÑ È¯ÀÚÀÇ 10³â ±¹¼ÒÁ¦¾îÀ²À» 82%·Î º¸°íÇÏ¿´À¸¸ç ÃÖ±Ù ¸î¸î randomized trial¿¡¼­´Â ¼ö
¼úÈÄ ¹æ»ç¼±Ä¡·á¿Í º¸Á¶Ç×¾ÏÈ­Çпä¹ýÀ» º´¿ëÇÑ È¯ÀÚ¿¡¼­ ±¹¼ÒÁ¦¾îÀ²ÀÇ Áõ°¡ »Ó ¾Æ´Ï¶ó »ýÁ¸
À² ¹× ¹«º´»ýÁ¸À²µµ Çâ»óµÇ¾úÀ½ÀÌ º¸°íµÇ°í ÀÖ´Ù. ÀÌ·¯ÇÑ ±¹¼Ò ÁøÇàµÈ À¯¹æ¾ÏÀÇ ÀûÀýÇÑ Ä¡
·á¸¦ À§Çؼ­´Â ¼ö¼ú, ¹æ»ç¼±Ä¡·á, Ç×¾ÏÈ­Çпä¹ý ¹× È£¸£¸ó¿ä¹ýÀÇ ÀåÁ¡À» È¿°úÀûÀ¸·Î »ì¸± ¼ö
ÀÖ´Â º´ÇÕ¿ä¹ýÀÇ Àû¿ëÀÌ ÇÊ¿äÇÏ´Ù°í ÇÏ°Ú´Ù. ÀÌ¿¡ ÀúÀÚµéÀº À¯¹æ¾ÏȯÀÚ¿¡¼­ ¼ö¼úÈÄ ¹æ»ç¼±
Ä¡·á°¡ ±¹¼ÒÁ¦¾îÀ² ¹× »ýÁ¸À²¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ¾Ë¾Æº¸°í À̵é ȯÀÚÀÇ ¿¹ÈÄÀÎÀÚ ¹× ½ÇÆоç»ó
À» ºÐ¼®ÇÏ¿© ¾ÕÀ¸·Î Ä¡·á¼ºÀûÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â ÀûÀýÇÑ Ä¡·á¹æħÀ» ¸ð»öÇØ º¸°íÀÚ º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose : This retrospective study was performed to evaluate the effect of
postoperative adjuvant radiation therapy of breast cancer on survival, failure patterns
and to identify unfavorable prognostic factors.
Materials and Methods : Seventy-seven patients were analysed retrospectively. Median
follow up period was 72 months. According to AJCC system, fifty-eight patients(75%)
were advanced than Stage ¥±b. Among 77 patients, 66 patients(86%) received
mastectomy and axillary LN dissection and the other 11 patients (14%) received partial
mastectomy and axillary LN dissection. Postoperative radiation therapy with 6 MV
X-ray was given to the chest wall and regional lymphatics with total dose of 50 to 55
Gy. Fifty-five Patients(71%) received CMF or CAF chemotherapy Prior to or after
radiation therapy.
Results : The 5 year and 10 year survival rate were 64.4% and 51.3%, respectively
and 5 year and 10 year disease free survival rate were 57.6% and 47.5%, respectively.
Median survival duration was 91 months. Of the 77 patients,59 patients were evaluable
for pattern of failure. Of these, eighteen patients(31%) failed. Initial failure pattern was
as follow: 7(12%) at locoregional, 3(5%) in distant metastasis, 8(14%) with locoregional
and distant metastasis. But the pattern of final failure at the time of last follow up was
contrasted. Distanf failure was the predominant pattern of failure with 29% of patients.
Overall survival and disease free survival was significantly influenced by 6 factors with
univariated analysis(p<0.05): AJC Stage, T stage, N Stage, number of involved axilliary
LN, SCL LN mets, failure pattern. By multivariate analysis the survival difference
continued to be significant in 3 factors : T stage, number of involved axillary LN,
failure pattern.
Conclusion : These data demonstrate high locoregional control and survival rate using
the combination of surgery and radiotherapy for the patients with locally advanced
breast cancer. But predominant failure pattern was distant dissemination. Therefore more
effective systemic therapy is needed to improve overall survival.

Å°¿öµå

Breast cancer; Postoperative radiation therapy; Locoregional control; Survival;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS